Treatment of chronic hepatitis B: focus on telbivudine.

Article Details

Citation

Lui YY, Chan HL

Treatment of chronic hepatitis B: focus on telbivudine.

Expert Rev Anti Infect Ther. 2009 Apr;7(3):259-68. doi: 10.1586/eri.09.6.

PubMed ID
19344240 [ View in PubMed
]
Abstract

Chronic hepatitis B is a worldwide health problem. Research interests have focused on the development of potent and safe antiviral agents with low resistance rates. Among these, telbivudine is an oral nucleoside analogue with specific activity against hepatitis B virus DNA polymerase. Various prospective, randomized clinical trials have demonstrated the potent efficacy of telbivudine in suppressing viral replication and achieving hepatitis B e antigen seroconversion. Telbivudine was also proved to be superior to lamivudine and adefovir dipivoxil. This article provides an overview of the pharmacokinetics, clinical efficacies, resistance profile and safety of telbivudine. A comparison of telbivudine with other oral antiviral agents is also highlighted.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
TelbivudineProtein PProteinHBV-F
Yes
Not AvailableDetails